166,843 Shares in Kodiak Sciences Inc. (NASDAQ:KOD) Bought by Peapod Lane Capital LLC

Peapod Lane Capital LLC acquired a new stake in Kodiak Sciences Inc. (NASDAQ:KOD - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 166,843 shares of the company's stock, valued at approximately $1,660,000. Kodiak Sciences accounts for approximately 1.6% of Peapod Lane Capital LLC's holdings, making the stock its 26th biggest holding. Peapod Lane Capital LLC owned about 0.32% of Kodiak Sciences as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently bought and sold shares of KOD. LJI Wealth Management LLC increased its holdings in Kodiak Sciences by 21.3% during the 3rd quarter. LJI Wealth Management LLC now owns 17,100 shares of the company's stock valued at $45,000 after acquiring an additional 3,000 shares in the last quarter. SG Americas Securities LLC lifted its holdings in shares of Kodiak Sciences by 61.4% in the fourth quarter. SG Americas Securities LLC now owns 20,684 shares of the company's stock valued at $206,000 after purchasing an additional 7,871 shares in the last quarter. Geode Capital Management LLC grew its position in shares of Kodiak Sciences by 1.7% in the third quarter. Geode Capital Management LLC now owns 768,740 shares of the company's stock valued at $2,007,000 after purchasing an additional 12,783 shares during the last quarter. State Street Corp increased its stake in shares of Kodiak Sciences by 1.8% during the 3rd quarter. State Street Corp now owns 816,634 shares of the company's stock worth $2,131,000 after purchasing an additional 14,711 shares in the last quarter. Finally, Sanctuary Advisors LLC acquired a new position in shares of Kodiak Sciences during the 2nd quarter worth approximately $36,000. Hedge funds and other institutional investors own 89.06% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on KOD shares. HC Wainwright reaffirmed a "neutral" rating and issued a $3.00 target price on shares of Kodiak Sciences in a research note on Friday, November 15th. Barclays upped their price objective on Kodiak Sciences from $3.00 to $4.00 and gave the company an "underweight" rating in a research report on Friday, November 15th. Finally, Jefferies Financial Group raised shares of Kodiak Sciences from a "hold" rating to a "buy" rating and set a $20.00 target price for the company in a research note on Monday, December 9th.

Kodiak Sciences Stock Performance

NASDAQ KOD traded up $0.16 during trading hours on Monday, hitting $5.26. 194,877 shares of the company's stock were exchanged, compared to its average volume of 392,843. The firm has a market capitalization of $276.78 million, a P/E ratio of -1.44 and a beta of 2.06. Kodiak Sciences Inc. has a 12-month low of $2.18 and a 12-month high of $11.60. The business's 50 day moving average is $7.99 and its 200-day moving average is $5.18.

Kodiak Sciences Company Profile

Kodiak Sciences Inc, a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.